ArticleAntimicrobial agents and chemotherapy2004
Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis.Infection · 2025Pooled it
- Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience.Antibiotics (Basel, Switzerland) · 2023Article
- New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended.Journal of clinical medicine · 2023Review
- Use of dalbavancin in infective endocarditis: a case series.JAC-antimicrobial resistance · 2021Article
- Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Drugs · 2015Review
- Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.Infectious diseases and therapy · 2015Article
- Review
- Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.Antimicrobial agents and chemotherapy · 2010Article
- Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.Clinical microbiology reviews · 2010Review
- Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review.Therapeutics and clinical risk management · 2008Article
- Dalbavancin (zeven), a novel glycopeptide for resistant gram-positive organisms.P & T : a peer-reviewed journal for formulary management · 2008Article
- Dalbavancin.Drugs · 2008Review
- Bactericidal activity and resistance development profiling of dalbavancin.Antimicrobial agents and chemotherapy · 2007Article
- Antipneumococcal activity of dalbavancin compared to other agents.Antimicrobial agents and chemotherapy · 2005Article
- Growth characteristics of and virulence factor production by group A Streptococcus during cultivation in human saliva.Infection and immunity · 2005Article
- Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.Antimicrobial agents and chemotherapy · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For the treatment of rabbit endocarditis, dalbavancin given once daily (10 mg/kg of body weight for 4 days) or as a single 40-mg/kg dose was active against Staphylococcus aureus with or without reduced susceptibility to glycopeptides, as expected from its good in vitro activity, even in broth supplemented with 90% serum and given its prolonged elimination half-life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.